Previous Close | 0.7500 |
Open | 0.7400 |
Bid | 0.0000 x 800 |
Ask | 0.0000 x 1300 |
Day's Range | 0.7193 - 0.7699 |
52 Week Range | 0.6500 - 15.4000 |
Volume | |
Avg. Volume | 212,135 |
Market Cap | 49.109M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for FRLN
Short-term investors could be interested in these businesses
Investment company Federated Hermes Prudent Bear Fund (Current Portfolio) buys PowerShares QQQ Trust Ser 1, iShares Russell 2000 ETF, iShares MSCI Emerging Markets ETF, SPDR Biotech ETF, iShares MSCI EAFE ETF, sells S&P 500 ETF TRUST ETF, Financial Select Sector SPDR, Health Care Select Sector SPDR, ARK Genomic Revolution ETF, Cisco Systems Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Federated Hermes Prudent Bear Fund.
Freeline Therapeutics Holdings plc (NASDAQ: FRLN) gave an update on its investigational Fabry disease treatment FLT190, currently in a Phase 1/2 trial, saying the candidate proved durable in the second patient tested. Fabry disease is an inherited metabolic disorder resulting from the absent or markedly deficient activity of lysosomal enzyme α-galactosidase A, or α-Gal A. Patient Two was dosed at the lowest dose cohort of 7.5e11 vg/kg and experienced a sustained and durable response with an incr